The effect of tibolone treatment on fasting blood sugar, insulin, insulin resistance and endothelial function in postmenopausal women: A meta-analysis of randomized controlled trials

Zhu, Yinghong; Zhu, Yinghong; Chen, Yan; Yan, Qingxin; Baradwan, Saeed; Găman, Mihnea‐Alexandru; Zanghelini, Fernando

doi:10.1016/j.exger.2021.111586

Cited by 5 publications

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous studies have proven that PS display lipid‐lowering properties via the regulation of high‐density lipoprotein cholesterol (HDL‐C), LDL‐C, TC, and triglycerides (TG) metabolism (Dumolt & Rideout, 2017; Sattar et al, 2010). However, as lipid abnormalities elevate cardiovascular risk and as women lose the protective role of estrogen in the postmenopausal period, the discovery of novel strategies to control the lipid profile is warranted in postmenopausal females (Zhu et al, 2021). Thus, PS represent a promising approach to the control of serum lipids concentrations in this population, yet evidence‐based recommendations derived from RCTs are needed to clarify their health benefits.…”

Section: Introductionmentioning

confidence: 99%

The effects of phytosterol and phytostanol supplementation on the lipid profile in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials

Xia

Xiang

Găman

et al. 2022

Phytotherapy Research

View full text Add to dashboard Cite

Various studies have proven that phytosterols and phytostanols (PS) are lipidlowering agents. These compounds play a role in regulating high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), and triglyceride (TG) metabolism. Although various drugs are available and are currently used to treat dyslipidemia, the management of lipid abnormalities during the postmenopausal period remains a challenge. Thus, scientists are trying to develop new strategies to reduce serum lipids concentrations using natural products.However, the impact of PS administration on serum lipids in postmenopausal women remains unclear. Hence, the purpose of this study was to assess the effect of PS supplementation on the lipid profile in postmenopausal women based on a systematic review of the literature and a meta-analysis of randomized controlled trials.PubMed/Medline, Scopus, Embase, and Web of Science were searched to identify suitable papers published until January 18, 2022. We combined the effect sizes with the DerSimonian and Laird method using a random effects model. PS supplementation resulted in a significant decrease in TC (weighted mean difference [WMD]: À16.73 mg/dl) and LDL-C (WMD: À10.06 mg/dl) levels. No effect of PS supplementation on TG (WMD: À1.14 mg/dl) or HDL-C (WMD: À0.29 mg/dl) concentrations was detected. In the stratified analysis, there was a notable reduction in TC and LDL-C levels when the PS dose was ≥2 g/day (TC: À22.22 mg/dl and LDL-C: À10.14 mg/dl) and when PS were administered to participants with a body mass index ≥25 kg/m 2 (TC: À20.22 mg/dl and LDL-C: À14.85 mg/dl). PS administration can decrease TC and LDL-C, particularly if the dose of administration is ≥2 g/day and if the participants are overweight or obese. Further high-quality studies are needed to firmly establish the clinical efficacy of PS usage in postmenopausal females.

show abstract

Section: Introductionmentioning

confidence: 99%

The effects of phytosterol and phytostanol supplementation on the lipid profile in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials

Xia

Xiang

Găman

et al. 2022

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…This is believed to be due to the accumulation of prothrombotic metabolites that may occur during the metabolic process of oral hormone therapy, leading to atherosclerotic effects, ischemia, and vascular cognitive decline ( Henderson and Popat, 2011 ; Scarabin-Carre et al, 2012 ). Although TIB is known to show a cardiovascular protection effect through its metabolite ( Del Rio et al, 2020 ), long-term use of TIB may also be associated with increased cardiovascular risks, such as CRP elevation and hyperthermia, which could lead to brain vessel wall injury ( Formoso et al, 2016 ; Zhu et al, 2021 ). A similar mechanism can explain this as the analysis result that topical estrogen is not associated with non-AD dementia occurrence.…”

Section: Discussionmentioning

confidence: 99%

Menopausal hormone therapy and risk of dementia: health insurance database in South Korea-based retrospective cohort study

Yuk,

Lee,

Park

2023

Front. Aging Neurosci.

View full text Add to dashboard Cite

IntroductionMenopausal hormone therapy (MHT) is used to alleviate the symptoms associated with menopause, despite the lack of recommendations for MHT in preventing dementia. Recent nationwide studies have explored the association between MHT and dementia risk, but the findings remain limited. This study aims to investigate the association between MHT and the incidence of Alzheimer’s disease (AD) and non-AD dementia using national population data from Korea.MethodsWe conducted a retrospective study using data from the National Health Insurance Service in Korea between January 1, 2002, and December 31, 2019. Women over 40 years were eligible for this study and classified into the MHT or non-MHT groups. The MHT group consisted of women who used Tibolone (TIB), combined estrogen plus progestin by the manufacturer (CEPM), estrogen, combined estrogen plus progestin by a physician (CEPP), and transdermal estrogen during menopause. We compared the risk of dementia between the MHT and non-MHT groups.ResultsThe study included 1,399,256 patients, of whom 387,477 were in the MHT group, and 1,011,779 were in the non-MHT group. The median duration of MHT was 23 months (range: 10–55 months). After adjusting for available confounders, we found that different types of MHT had varying effects on the occurrence of dementia. TIB (HR 1.041, 95% confidence interval (CI) 1.01–1.072) and oral estrogen alone (HR 1.081, 95% CI 1.03–1.134) were associated with a higher risk of AD dementia. In contrast, there was no difference in the risk of AD dementia by CEPM (HR 0.975, 95% CI 0.93–1.019), CEPP (HR 1.131, 95% CI 0.997–1.283), and transdermal estrogen (HR 0.989, 95% CI 0.757–1.292) use. The use of TIB, CEPM, and oral estrogen alone increased the risk of non-AD dementia (HR 1.335, 95% CI 1.303–1.368; HR 1.25, 95% CI 1.21–1.292; and HR 1.128, 95% CI 1.079–1.179; respectively), but there was no risk of non-AD dementia in the other MHT groups (CEPP and topical estrogen).ConclusionOur findings indicate that MHT has varying effects on the incidence of AD and non-AD dementia. Specifically, TIB, CEPM, and oral estrogen alone increase the risk of non-AD dementia, while transdermal estrogen is not associated with dementia risk. It is essential to consider the type of MHT used when assessing the risk of dementia in women.

show abstract

The Effect of Anastrozole on the Lipid Profile: Systematic Review and Meta-analysis of Randomized Controlled Trials

Alomar¹,

Okunade²,

Varkaneh³

et al. 2022

Clinical Therapeutics

View full text Add to dashboard Cite

The effect of tibolone treatment on fasting blood sugar, insulin, insulin resistance and endothelial function in postmenopausal women: A meta-analysis of randomized controlled trials

Cited by 5 publications

References 45 publications

The effects of phytosterol and phytostanol supplementation on the lipid profile in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials

The effects of phytosterol and phytostanol supplementation on the lipid profile in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials

Menopausal hormone therapy and risk of dementia: health insurance database in South Korea-based retrospective cohort study

The Effect of Anastrozole on the Lipid Profile: Systematic Review and Meta-analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About